Navigation Links
Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World
Date:5/6/2010

is, Haemoplilus influenza type b infection and hepatitis B. Quinvaxem(R) is ready for use without further preparation steps by healthcare workers in the field, which offers major healthcare advantages for these countries with a challenging infrastructure and hygiene problems.

This latest order brings the overall value of tenders awarded to Crucell for the period of 2010-2012 to $410 million. This is in addition to the $500 million obtained over the tender period 2007-2009. They bring the total value of contracts awarded since the launch of Quinvaxem(R) at the end of 2006 to $910 million. During the first tender round in 2006, Crucell was initially awarded $230 million (December 2006) and received additional incremental awards of $130 million and $140 million in May and September 2008, respectively.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the US Securities and Exchange Commission on April 7, 2010, in the section entitled 'Risk Factors'. The Company prepares its financial statements under International Financial Reporting Standards (IFRS).

About Crucell

Crucell N.V. (NYSE Euronext, NASDAQ: CRXL<
'/>"/>

SOURCE Crucell N.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
2. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
3. DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
4. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... MILAN , October 27, 2014 ... the right to produce, exhibit and sell its ... sought to impeach their patent.      ... After four years of fighting, the definitive judgement ... designs and produces innovative and accessible hi-tech prostheses ...
(Date:10/27/2014)... 2014 Called the NOAH Protocol, ... several types of pediatric brain cancer. The implications ... over 30 years of research and development. Amber ... that one mom's determination can make a difference. ... trick-or-treating, and it’s only fitting that we’ve received ...
(Date:10/26/2014)... 26, 2014 The report "Data ... Network Security Equipment, WAN Optimization Appliances]: Global Advancements, ... the data center networking market into various segments ... The report also identifies the factors driving this ... it along with the future roadmaps. , Browse ...
(Date:10/25/2014)... According to new market research ... Types (Colocation, Enterprise, Telecom), by Design Types (Electrical, ... 2, Tier 3, Tier 4) - Global Forecast ... the Data Center Construction Market into various segments ... This research report also identifies the factors driving ...
Breaking Biology Technology:Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... PhD, Further Strengthens Kendle,s Global ... Regulatory Affairs Organization, ... ), a,leading, global full-service clinical research organization, today,announced that ... Affairs Consultant specializing in providing regulatory affairs,guidance to the ...
... CORNER, N.J., Aug. 10 Reliant Pharmaceuticals,Inc. today announced ... S-1,with the Securities and Exchange Commission for an initial ... that Reliant,will sell newly issued common stock and that ... of Reliant,s common stock. Goldman, Sachs & Co. ...
... has Initiated a Phase II study of R1507 ... for the Treatment of ... today that its partner, Roche has initiated a Phase II,clinical study ... antibody was created by Genmab under the company,s,agreement with Roche and ...
Cached Biology Technology:Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant 2Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant 3Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering 2Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma 2
(Date:10/28/2014)... Individual differences in moving activity in a novel ... to angling, according to an experimental study completed ... Finnish Game and Fisheries Research Institute. The study ... groups and authentic angling trials to analyse if ... trout reared in traditional and enriched hatchery rearing ...
(Date:10/27/2014)... a scientific one-two punch with a pair of papers ... sticky ends. , Collagen is the most common protein ... fibrous tissues that support cells and hold organs together. ... for tissue engineering and cosmetic and reconstructive medicine. , ... synthetic collagen for a decade, teasing out the details ...
(Date:10/27/2014)... day, about a third of blacks hold onto sodium ... an hour after the stress that raised their pressure ... know how chronic mental stress, obesity, and inflammation conspire ... the best ways to treat it. , "We ... – these patients have increased damage to their hearts, ...
Breaking Biology News(10 mins):Fish 'personality' linked to vulnerability to angling 2'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3Researchers look for the best way to help shake too much sodium 2Researchers look for the best way to help shake too much sodium 3Researchers look for the best way to help shake too much sodium 4
... one of many important crop species that is unsuited ... used to work with crops. Researchers, reporting in the ... first high-throughput forward and reverse genetics tool for the ... breeders around the world.. Researchers from the INRA ...
... ambitious expedition led by scientists at Scripps Institution of ... little-known islands in the central Pacific Ocean has yielded ... threats from human activities. The exploration of four ... approximately a thousand miles south of Hawaii, has produced ...
... The reductionist goal of cell biology is to ... do this, one needs to quantify molecular concentrations ... execute and regulate various complex processes. For ... characterized by highly localized, transient component processes, the ...
Cached Biology News:Scientists unravel the genetic coding of the pea 2Scripps expedition provides new baseline for coral reef conservation 2Scripps expedition provides new baseline for coral reef conservation 3
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
... is a type I eukaryotic topoisomerase that ... (also called right- and left-handed supercoils) from ... reaction is a covalently closed, circular DNA ... DNA Topoisomerase I does not absolutely require ...
... Topoisomerase I from vaccinia virus is a ... positive and negative superhelical turns (also called ... DNA. The product of the reaction is ... positive or negative superhelical turns. DNA Topoisomerase ...
... DNA Modification Kit contains reagents required to ... sample. In the bisulfite reaction, all unmethylated ... to uracils, while 5-methylcytosines remain unaltered. Thus, ... differ depending on whether the DNA is ...
Biology Products: